Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

Inhibition of autophagy potentiated the anti-tumor effects of VEGF and CD47 bispecific therapy in glioblastoma

(2018) Xuyao Zhang et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Blocking “don't eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review

(2018) Atlantis Russ et al.   BLOOD REVIEWS

Disrupting CD47-SIRPα axis alone or combined with autophagy depletion for the therapy of glioblastoma

(2018) Xuyao Zhang et al.   CARCINOGENESIS

PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival

(2017) Cristina Alessi et al.   MELANOMA RESEARCH

Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors

(2017) Sharareh Gholamin et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

A novel and promising therapeutic approach for NSCLC: recombinant human arginase alone or combined with autophagy inhibitor

(2017) Weitao Shen et al.   Cell Death & Disease

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer

(2017) Paola A. Betancur et al.   Nature Communications

Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non–Small Cell Lung Cancer

(2017) Xuyao Zhang et al.   Cancer Immunology Research

Targeting asparagine and autophagy for pulmonary adenocarcinoma therapy

(2016) Boyang Zhang et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

SIRP -Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells

(2016) E. C. Piccione et al.   CLINICAL CANCER RESEARCH

Targeting T Cell Co-receptors for Cancer Therapy

(2016) Margaret K. Callahan et al.   IMMUNITY

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Ten years of anti-vascular endothelial growth factor therapy

(2016) Napoleone Ferrara et al.   NATURE REVIEWS DRUG DISCOVERY

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

(2016) Gabriela Jiménez-Valerio et al.   Cell Reports

A novel engineered VEGF blocker with an excellent pharmacokinetic profile and robust anti-tumor activity

(2015) Lily Liu et al.   BMC CANCER

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals

(2015) M. N. McCracken et al.   CLINICAL CANCER RESEARCH

CD47 blockade as another immune checkpoint therapy for cancer

(2015) Robert H Vonderheide   NATURE MEDICINE

Intratumoral Myeloid Cells Regulate Responsiveness and Resistance to Antiangiogenic Therapy

(2015) Lee B. Rivera et al.   Cell Reports

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

(2014) Naveen S. Vasudev et al.   ANGIOGENESIS

Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia

(2014) Rakesh K. Jain   CANCER CELL

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Deciphering and Reversing Tumor Immune Suppression

(2013) Greg T. Motz et al.   IMMUNITY

Innate and adaptive immune cells in the tumor microenvironment

(2013) Thomas F Gajewski et al.   NATURE IMMUNOLOGY

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer

(2012) M. Terme et al.   CANCER RESEARCH

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE